Evidence map›Paper›PMID 31831728›Full record

ArticleCell death & disease2019

The novel circCLK3/miR-320a/FoxM1 axis promotes cervical cancer progression.

Hanqing Hong, Hai Zhu, Shujun Zhao, Kaili Wang, Nan Zhang, Yun Tian, Yan Li, Yaping Wang, Xiaofeng Lv, Tianxiang Wei and 8 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 3 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 3 syntheses or guidelines pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Investigation of potential biomarkers associated with relapse in cervical cancer: miRNA-320a-3p and miRNA-136-5p.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026
    Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Circular RNAs and Cancers.Advances in experimental medicine and biology · 2025
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Hanqing HongDepartment of obstetrics and gynecology, The Third Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Hai ZhuDepartment of obstetrics and gynecology, The Third Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Shujun ZhaoDepartment of obstetrics and gynecology, The Third Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Kaili WangDepartment of obstetrics and gynecology, The Third Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Nan ZhangDepartment of obstetrics and gynecology, The Third Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Yun TianDepartment of obstetrics and gynecology, The Third Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Yan LiDepartment of obstetrics and gynecology, The Third Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Yaping WangDepartment of obstetrics and gynecology, The Third Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Xiaofeng LvDepartment of obstetrics and gynecology, The Third Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Tianxiang WeiDepartment of obstetrics and gynecology, The Third Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Yan LiuDepartment of obstetrics and gynecology, The Third Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Suzhen FanDepartment of obstetrics and gynecology, The Third Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Yang LiuDepartment of medical genetics and cell biology, School of Basic Medical Sciences of Zhengzhou University, 450052, Zhengzhou, China.
Yuan LiDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Aojie CaiGenetics and prenatal diagnosis center, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Shuo JinDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China.
Qiaohong QinDepartment of obstetrics and gynecology, The Third Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China. qin_qiaohong@126.com.
Hongyu LiDepartment of obstetrics and gynecology, The Third Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, China. fuliuzhongdianshiyanshi@gs.zzu.edu.cn.
Third Affiliated Hospital of Zhengzhou University · CNFirst Affiliated Hospital of Zhengzhou University · CNZhengzhou University · CN

Funding

Natural Science Foundation of Henan Province (Henan Province Natural Science Foundation) 162300410269
6 · The paper itself

Abstract

As a new class of non-coding RNA, circular RNAs (circRNAs) play crucial roles in the development and progression of various cancers. However, the detailed functions of circRNAs in cervical cancer have seldom been reported. In this study, circRNA sequence was applied to detect the differentially expressed circRNAs between cervical cancer tissues and adjacent normal tissues. The relationships between circCLK3 level with clinicopathological characteristics and prognosis were analyzed. In vitro CCK-8, cell count, cell colony, cell wound healing, transwell migration and invasion, and in vivo tumorigenesis and lung metastasis models were performed to evaluate the functions of circCLK3. The pull-down, RNA immunoprecipitation (RIP), luciferase reporter and rescue assays were employed to clarify the interaction between circCLK3 and miR-320a and the regulation of miR-320a on FoxM1. We found that the level of circCLK3 was remarkably higher in cervical cancer tissues than in adjacent normal tissues, and closely associated with tumor differentiation, FIGO stage and depth of stromal invasion. Down-regulated circCLK3 evidently inhibited cell growth and metastasis of cervical cancer in vitro and in vivo, while up-regulated circCLK3 significantly promoted cell growth and metastasis in vitro and in vivo. The pull-down, luciferase reporter and RIP assays demonstrated that circCLK3 directly bound to and sponge miR-320a. MiR-320a suppressed the expression of FoxM1 through directly binding to 3'UTR of FoxM1 mRNA. In addition, FoxM1 promoted cell proliferation, migration, and invasion of cervical cancer, while miR-320a suppressed cell proliferation, migration, and invasion through suppressing FoxM1, and circCLK3 enhanced cell proliferation, migration and invasion through sponging miR-320a and promoting FoxM1 expression. In summary, circCLK3 may serve as a novel diagnostic biomarker for disease progression and a promising molecular target for early diagnoses and treatments of cervical cancer.

Indexed as

AgedCarcinogenesisCell DifferentiationCell Line, TumorCell MovementCell ProliferationDisease-Free SurvivalDisease ProgressionFemaleForkhead Box Protein M1Gene Expression Regulation, NeoplasticHumansMicroRNAsMiddle AgedNeoplasm MetastasisPrognosisClk dual-specificity kinasesForkhead Box Protein M1FOXM1 protein, humanMicroRNAsMIRN320 microRNA, humanProtein Serine-Threonine KinasesProtein-Tyrosine KinasesRNA, Circular

Identifiers

PMID31831728
PMCPMC6908646
OpenAlexW2994788718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.